Bone Biologics (BBLG) Gains from Investment Securities (2023 - 2026)
Bone Biologics (BBLG) posted quarterly Gains from Investment Securities of -$498.0 for Q4 2025, up 96.16% year-over-year from -$253.88 in Q4 2024, and up 58.91% quarter-over-quarter from -$1212.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Gains from Investment Securities for 3 consecutive years, with -$498.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 96.16% year-over-year to -$498.0; the TTM figure through Dec 2025 stood at -$3967.0 (up 92.23% YoY), while the FY2025 annual figure was -$3967.0, up 92.23% from the prior year.
- Gains from Investment Securities grew to -$498.0 in Q4 2025 per BBLG's latest filing, from -$1212.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $562918.0 in Q1 2023 and bottomed at -$1.3 million in Q2 2023.
- Historically, Gains from Investment Securities has averaged -$78978.3 across 3 years, with a median of -$6070.0 in 2024.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 106.21% — and 2025, when it slumped 112.15%.
- Bone Biologics' Gains from Investment Securities stood at -$24763.0 in 2023, then jumped by 47.67% to -$12959.0 in 2024, then jumped by 96.16% to -$498.0 in 2025.
- Business Quant data shows BBLG's Gains from Investment Securities at -$498.0 in Q4 2025, -$1212.0 in Q3 2025, and -$902.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 108.00 |
| Dec 31, 2025 | -498.00 |
| Sep 30, 2025 | -1,212.00 |
| Jun 30, 2025 | -902.00 |
| Mar 31, 2025 | -1,355.00 |
| Dec 31, 2024 | -12,959.00 |
| Sep 30, 2024 | 9,974.00 |
| Jun 30, 2024 | -10,785.00 |
| Mar 31, 2024 | -37,311.00 |
| Dec 31, 2023 | -24,763.00 |
| Sep 30, 2023 | -160,645.00 |
| Jun 30, 2023 | -1.27 Mn |
| Mar 31, 2023 | 562,918.00 |